|

The most undervalued pharma penny-stocks in Canada

The most undervalued pharma penny-stocks in Canada

Penny stocks can be a high-risk investment, but they can also offer great returns. Not all companies with shares being traded in this area of the stock market end up turning much profit, but some exceed the expectations of even experienced analysts. Penny stocks offer investors a unique opportunity to acquire shares at a low price and enjoy a great return if the companies succeed.

Here are 3 Canadian pharma penny-stocks to watch in the coming months.

VentriPoint Diagnostics (OTC: VPTDF)

Incorporated in 2004, Ventripoint Diagnostics, Ltd. is a medical device company headquartered in Toronto, Canada. The company specializes in the development and commercialization of diagnostic tools that monitor heart disease patients. The company’s flagship product is an imaging system that can be used to make 3D models featuring critical volume and functional measurements of a patient’s heart chambers.

VentriPoint has also recently expanded from the medical imaging systems and developed a suite of applications for various heart diseases and imaging modalities, including Covid-19 related heart issues. The company has managed to tough it out on the stock market with a market cap of 37.645 million. The 52-week range of the stock price is $0.06 to $0.55, with a closing price of $0.24. The upside of the stock depends on innovations at VentriPoint Diagnostics that are expected to be revealed in 2022. While the share value has declined since the previous year’s high of 0.55, some analysts are optimistic that the value will eventually surpass earlier resistance points.

Microbix Biosystems (OTCQX: MBXBF) (XTSE: MBX)

Microbix Biosystems is a life science company that has been around since 1988. The Canadian company develops and commercializes proprietary biological and technological solutions for health and wellbeing. The company primarily caters to North America and Europe and manufactures biological materials for the diagnostics industry.

Microbix received recognition and financial stability after manufacturing a critical range of antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab testing, assay development, and validation. The company specializes in streamlining clinical workflows. Headquartered in Mississauga, Canada, Microbix Biosystems, Inc. is applying its biological expertise to develop other products, like a viral transport medium (DxTM), which stabilizes patient samples for lab testing. Microbix has earned revenue by selling QAPs to lab accreditation organizations, diagnostic companies, and clinical labs.

Microbix had a profitable year in 2021, with revenues increasing 77% from 2020. The company achieved record-high revenues of $18.6 million, with stronger sales and better gross margins leading to a net income of $3,233,390. The turnaround was significant, given the previous year’s net loss of $6,227,525. The news of 2021 earnings was reflected quickly in the stock market with the share value reaching an all-time high.

Microbix shares are currently traded at $0.5255 on February 8, 2022. The market cap of 68.29 million and a share volume of only 6,000 show some potential upside. Share values have shown a 52-week range of $0.40 - $0.72. The company is scheduled to release quarterly earnings on February 10, 2022, which will likely have an impact on the stock price.

InnoCan Pharma (OTCQB: INNPF) (CSE: INNO) (FSE: IP4)

Recent worldwide adoption and acceptance of Cannabidiol (CBD) infused treatments and products has opened many new doors in the pharmaceutical industry. One Israeli pharmaceutical technology company that is proving to be a rising star in medical technologies and the stock market is InnoCan Pharma. Founded in 2018, the company has made cutting-edge breakthroughs for the future of Cannabidiol (CBD) loaded delivery systems.

The company specializes in the research, development, and production of several different platforms to combine CBD with other pharmaceuticals, as well as the CBD-integrated pharmaceuticals themselves. The current lines of business at InnoCan include injections, exosomes, topicals, and healing cosmetic products. The company derives its early success from a novel combination of technologies with pharmaceutical breakthroughs that allow InnoCan to target specialized markets and gain first-mover advantages.  

InnoCan has already made significant accomplishments with research and development and commercial products. The company has achieved semi-commercial production of exosomes and has a total of 14 families of patent applications. InnoCan has launched a B2C sales platform and secured distribution agreements in more than seven countries. The products and technological advancements continue to stabilize the financial position of InnoCan, which has raised more than $28 million CAD by exercising warrants and fundraising.

InnoCan shows a current equity capital base of roughly $28 million, with an outstanding option to convert another $2 million of warrants. The Israeli company continued to invest resources into development during 2021, which translated very well for investors. In March 2021, the company entered the stock market through the Canadian Securities Exchange, listed at $0.37 per share. In its introductory year, the stock prevailed with a 52-week range of $0.30 - $1.65 and a share volume of 30,505.

Author

Joshua Horowitz

Joshua Horowitz

Independent Analyst

Joshua Horowitz a writer and blogger active in the fields of cyber, pharma, blockchain, cannabis and more. Josh is associated with the Future Markets Research Tank, a digital brand market thoughts and commentary on emerging technologies and markets.

More from Joshua Horowitz
Share:

Editor's Picks

AUD/USD hits yearly lows near 0.6650

AUD/USD has traded on the back foot once again, this time slipping back to the 0.6650 zone to clinch new yearly lows on Thursday. The continuation of the downward trend has come on the back of marginal gains in the Greenback, while poor jobs report in Oz added to the sour sentiment.


USD/JPY keeps its range near 159.50 despite hawkish BoJ Ueda

The Dollar rose against most major currencies but not the Yen, which is backed by intervention warnings near 160.00 and hawkish BoJ Ueda's commentary. USD/JPY is keeping its range around 159.50 in Asia on Thursday after a few sessions of small declines from a high just above 160.00. That high was its highest since early September.



Gold hits fresh lows near $3,680

Gold adds to the weekly pullback on Thursday, breaching below the $3,700 mark per troy ounce for the first time since September 2025. The precious metal’s persistent decline follows steady bets for further Fed tightening amid the solid performance of the US Dollar.

Ether.fi Price Forecast: ETFFI bulls stage recovery above $0.50
Ether.fi (ETHFI) is trading above $0.50 on Thursday.
Stocks rally in anticipation of $107 billion Anthropic IPO

AI stocks are gaining as strong demand for Anthropic's IPO lifts sentiment after recent selling. Anthropic is set to make history this week as the developer of the Claude artificial intelligence platform begins trading on the NASDAQ exchange under the ticker symbol ANT.

Gold's 14-month low looks mild next to Silver's fall from $121 to $44
Gold has lost a third of its value since January as traders bet on more Federal Reserve rate increases. Silver has lost nearly two-thirds, because the buyers still holding Gold up have no equivalent in the Silver market. Gold is trading below $3,700 for the first time since September 2025, a little more than a third under the record near $5,600 it set in late January.